Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

5.2K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
5.2K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Cancer Therapy (excl. Chemotherapy And Radiation Therapy)
  11. Codelivery Of Methotrexate And Silibinin By Niosome Nanoparticles For Enhanced Chemotherapy Of Ct26 Colon Cancer Cells.

Codelivery of methotrexate and silibinin by niosome nanoparticles for enhanced chemotherapy of CT26 colon cancer cells.

Masoumeh Sharifi-Azad1, Masoumeh Kaveh Zenjanab2, Mohammad Shahpouri1

  • 1Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.

Biomedical Materials (Bristol, England)
|July 2, 2024

Related Experiment Videos

Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles
10:26

Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles

Published on: November 1, 2017

8.4K
Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

10.9K
Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
09:56

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

14.9K

View abstract on PubMed

Summary
This summary is machine-generated.

Niosome nanoparticles co-loaded with silibinin and methotrexate show enhanced efficacy against colon cancer. This novel approach reduces drug toxicity and overcomes multi-drug resistance, offering a promising strategy for cancer therapy.

Area of Science:

  • Nanomedicine
  • Oncology
  • Drug Delivery

Background:

  • Colon cancer (CC) is a prevalent malignancy with treatment challenges including severe side effects and multi-drug resistance (MDR) from chemotherapy.
  • Niosome nanocarriers offer a solution by minimizing drug dose and toxicity, enabling co-delivery of incompatible drugs for combination therapy.

Purpose of the Study:

  • To develop and evaluate niosome nanoparticles (NPs) co-encapsulating silibinin (Sil) and methotrexate (MTX) for enhanced colon cancer therapy.
  • To assess the in vitro efficacy of these Niosome-based Methotrexate-Silibinin (Nio@MS) nanoparticles against CT26 colon cancer cells.

Main Methods:

  • Sil (hydrophobic) and MTX (hydrophilic) were co-loaded into niosomes using the thin-film hydration (TFH) method, forming Nio@MS NPs.
  • Characterization of Nio@MS NPs for morphology, size (∼100 nm), and zeta potential (-10 mV).
Keywords:
codeliverycolon carcinomamethotrexateniosome

Related Experiment Videos

Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles
10:26

Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles

Published on: November 1, 2017

8.4K
Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

10.9K
Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
09:56

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

14.9K
  • In vitro cytotoxicity assays were performed to determine the IC50 values and compare Nio@MS with individual drugs and their combination.

    • Main Results:

    • Nio@MS NPs exhibited ideal characteristics: spherical morphology, ∼100 nm size, and -10 mV zeta potential.
    • The IC50 of Nio@MS (∼2.6 µg ml⁻¹) was significantly lower than MTX-Sil (∼6.86 µg ml⁻¹), Sil (18.46 µg ml⁻¹), and MTX (9.8 µg ml⁻¹).
    • Nio@MS significantly reduced cell adhesion, induced apoptosis, upregulated BAX and caspase 3, and downregulated BCL2 expression.

    Conclusions:

    • Niosome-based co-delivery of Sil and MTX (Nio@MS) enhances drug cytotoxicity and anti-cancer potential against colon cancer.
    • This nanocarrier system effectively reduces required drug dosage and overcomes multi-drug resistance (MDR).
    • Niosomes represent a promising platform for combination chemotherapy in colon cancer treatment.
    silibinin